Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating Safety and Efficacy of MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Combination With Low-Dose CsA, Tac or Sir in Comparison to Current Standard Immunosuppression (MMF, CsA and Corticosteroids) in Renal Tx
Brief Summary: To determine the renal function, as expressed by the glomerular filtration rate at 12 months, in renal transplant recipients receiving mycophenolate mofetil, daclizumab, and corticosteroids as mainstay immunosuppression in combination with low-dose cyclosporine, tacrolimus, or sirolimus, and compare it to that of renal transplant recipients receiving standard immunosuppression with mycophenolate mofetil, normal dose cyclosporine and corticosteroids.


Options:
A: Arm Label: 1: Myfortic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolate Sodium Delayed Release Tablets | Arm Label: 2. Cellcept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolate Mofetil | Intervention Type: DRUG; Name: Mycophenolate Sodium Delayed Release Tablets; Assigned to Arm(s): 1: Myfortic | Intervention Type: DRUG; Name: Mycophenolate Mofetil; Assigned to Arm(s): 2. Cellcept
B: Intervention Type: DRUG; Name: daclizumab; Assigned to Arm(s): N/A
C: Arm Label: Low-dose Everolimus Group; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Arm Label: High-dose Everolimus Group; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolic Acid (MPA), Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Mycophenolic Acid (MPA); Assigned to Arm(s): Control Group | Intervention Type: DRUG; Name: Cyclosporine A (CsA); Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Basiliximab; Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group
D: Arm Label: Everolimus + Reduced dose of cyclosporine; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Basiliximab, Drug: Cyclosporine A, Drug: Corticosteroid | Arm Label: Mycophenolate mofetil (MMF) + Standard dose of cyclosporine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolate mofetil (MMF), Drug: Basiliximab, Drug: Cyclosporine A, Drug: Corticosteroid | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus + Reduced dose of cyclosporine | Intervention Type: DRUG; Name: Mycophenolate mofetil (MMF); Assigned to Arm(s): Mycophenolate mofetil (MMF) + Standard dose of cyclosporine | Intervention Type: DRUG; Name: Basiliximab; Assigned to Arm(s): Everolimus + Reduced dose of cyclosporine, Mycophenolate mofetil (MMF) + Standard dose of cyclosporine | Intervention Type: DRUG; Name: Cyclosporine A; Assigned to Arm(s): Everolimus + Reduced dose of cyclosporine, Mycophenolate mofetil (MMF) + Standard dose of cyclosporine | Intervention Type: DRUG; Name: Corticosteroid; Assigned to Arm(s): Everolimus + Reduced dose of cyclosporine, Mycophenolate mofetil (MMF) + Standard dose of cyclosporine

Answer: B